Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gut

• Publication date

  2014-07-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gutjnl-2014-307498PMID 25080450
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

  2014cited by this paper
• P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL

  2014cited by this paper
• Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials

  2014cited by this paper
• Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

  2014cited by this paper
• PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

  2013cited by this paper
• 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.

  2012cited by this paper
• Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

  2012cited by this paper
• Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

  2012cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2011cited by this paper
• A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

  2011cited by this paper
• The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein.

  2011cited by this paper
• In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A

  2011cited by this paper
• A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

  2011cited by this paper
• Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

  2011cited by this paper
• Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

  2011cited by this paper
• Hepatitis C virus genotype 4 therapy: progress and challenges

  2011cited by this paper
• Insulin resistance and sustained virological response in hepatitis C: from bench to bedside

  2011cited by this paper
• The global health burden of hepatitis C virus infection

  2011cited by this paper
• The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

  2011cited by this paper
• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

  2010cited by this paper
• A review of the treatment of chronic hepatitis C virus infection in cirrhosis.

  2010cited by this paper
• Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

  2010cited by this paper
• Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

  2010cited by this paper
• ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

  2010cited by this paper
• Diagnosis, management, and treatment of hepatitis C: An update

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• The global burden of hepatitis C

  2009cited by this paper
• The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

  2006cited by this paper
• Prevalence of hepatitis C virus infection in the United States.

  1999cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper

• Hepatitis C Elimination in Egypt: Story of Success

  2024cites this paper
• The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study

  2024cites this paper
• Correlation of Serum Hepatitis C Viral Load and Immunobiochemical biomarkers in Combined Therapy Treated Patients

  2023cites this paper
• Breakthroughs in hepatitis C research: from discovery to cure

  2022cites this paper
• Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes

  2021cites this paper
• The Impact of IL28B Gene Polymorphisms on Drug Responses

  2021cites this paper
• Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

  2020cites this paper
• Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C

  2019cites this paper
• Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment

  2019cites this paper
• Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.

  2019cites this paper
• New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.

  2019cites this paper
• Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients

  2019cites this paper
• Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients

  2019cites this paper
• The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex

  2018cites this paper
• Safety, Tolerability, and Associated Side Effects of Direct- Acting Antivirals

  2018cites this paper
• Predictors of disease progression and outcome in chronic hepatitis C virus infection

  2018cites this paper
• Management of hepatitis C infection in the era of direct-acting antiviral therapy

  2018cites this paper
• Evolution of efficacious pangenotypic hepatitis C virus therapies

  2018cites this paper
• [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012].

  2018cites this paper
• Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection

  2018cites this paper
• Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt

  2018cites this paper
• Real-world challenges for hepatitis C virus medications: a critical overview

  2018cites this paper
• Protease inhibitor therapy for hepatitis C virus-infection

  2018cites this paper
• Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

  2018cites this paper
• S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“

  2018cites this paper
• Improving ascertainment and treatment rates of chronic viral hepatitis

  2017cites this paper
• Direct-acting antivirals for chronic hepatitis C.

  2017cites this paper
• Safety and efficacy of direct‐acting antivirals for the treatment of chronic hepatitis C in a real‐world population aged 65 years and older

  2017cites this paper
• Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

  2017cites this paper
• Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection

  2017influential citation
• Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens

  2017cites this paper
• Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

  2017cites this paper
• Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.

  2017cites this paper
• Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients

  2017cites this paper
• Hepatitis C treatment from “response‐guided” to “resource‐guided” therapy in the transition era from interferon‐containing to interferon‐free regimens

  2017cites this paper
• Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study

  2017cites this paper
• INTRA-ABDOMINAL INFECTIONS , HEPATITIS , AND GASTROENTERITIS ( T STEINER , SECTION EDITOR ) Hepatitis C Virus-Genotype 3 : Update on Current and Emergent Therapeutic Interventions

  2017cites this paper
• Development and validation of a high-throughput system for the genotyping of Hepatitis C Virus

  2017cites this paper
• Resistance to Direct-Acting Antiviral Agents in Treatment of Hepatitis C Virus Infections

  2017influential citation
• Direct-acting antivirals for chronic hepatitis C.

  2017cites this paper
• Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6.

  2017cites this paper
• Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review.

  2017cites this paper
• Protease inhibitors for the treatment of hepatitis C virus infection

  2017cites this paper
• Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions

  2017cites this paper
• Synthesis of Novel Daclatasvir amino acid analogues for NS5A hepatitis-c virus inhibitor

  2017cites this paper
• Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies

  2017cites this paper
• Treatment of Chronic Hepatitis C - August 2017 Update

  2017cites this paper
• Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients

  2017cites this paper
• Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

  2017cites this paper
• Treatment Options for HCV Genotype-4

  2016cites this paper
• Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b

  2016cites this paper
• Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens

  2016cites this paper
• Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis

  2016cites this paper
• Recent Advances in Antiviral Therapy for Chronic Hepatitis C

  2016cites this paper
• Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence

  2016influential citation
• Advances in hepatitis C therapy: What is the current state - what come's next?

  2016cites this paper
• Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis

  2016influential citation
• New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs)

  2016cites this paper
• Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

  2016cites this paper
• Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview

  2016cites this paper
• Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease

  2016cites this paper
• The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

  2016cites this paper
• Management of hepatitis C genotype 4 in the directly acting antivirals era

  2016cites this paper
• Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.

  2016cites this paper
• Daclatasvir

  2016cites this paper
• Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.

  2016cites this paper
• Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.

  2016cites this paper
• Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24

  2016cites this paper
• Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

  2016cites this paper
• Interferon lambda 4 genotypes and resistance‐associated variants in patients infected with hepatitis C virus genotypes 1 and 3

  2016cites this paper
• Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA.

  2016cites this paper
• Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

  2016cites this paper
• Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies

  2016cites this paper
• Systematic review: current concepts and challenges for the direct‐acting antiviral era in hepatitis C cirrhosis

  2016cites this paper
• In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS 5 A Inhibitor Ledipasvir

  2016influential citation
• 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph.

  2016cites this paper
• In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

  2016influential citation
• Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection

  2016cites this paper
• Developing new models to predict treatment outcome in patients with chronic hepatitis C infection

  2016cites this paper
• Daclatasvir in hepatitis C virus infection: a guide to its use in the EU

  2016cites this paper
• Manufacturer for United States

  2016cites this paper
• Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C

  2016cites this paper
• Quantifying the evolutionary potential and constraints of a drug-targeted viral protein

  2016influential citation
• Daclatasvir/peginterferon lambda‐1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa‐2a/ribavirin

  2016cites this paper
• Daclatasvir in hepatitis C virus infection: a guide to its use in the EU

  2016influential citation
• Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection

  2015influential citation
• Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.

  2015cites this paper
• Daclatasvir for the treatment of chronic hepatitis C

  2015cites this paper
• The New Era of Hepatitis C Virus Therapy

  2015cites this paper
• Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.

  2015cites this paper
• Hepatitis C virus treatment in the real world: optimising treatment and access to therapies

  2015cites this paper
• Nutzen und Risiken der zulassungsüberschreitenden Arzneimittelanwendung in der ambulant-ärztlichen Versorgung

  2015influential citation
• BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 Update September 2014: Consensus statement on the guidelines for treating hepatitis C in patients with HIV

  2015cites this paper
• Kroonilise C-hepatiidi ravi

  2015cites this paper
• Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment

  2015cites this paper
• Advances in hepatitis C therapies

  2015cites this paper
• From non-A, non-B hepatitis to hepatitis C virus cure.

  2015cites this paper
• Hepatitis C genotype 4: The past, present, and future.

  2015cites this paper
• High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

  2015cites this paper
• Hepatitis C treatment in patients on the liver transplant waiting list

  2015cites this paper